Related Experiment Video
Updated: Jun 14, 2025
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.7K
Immune checkpoint blockade: timing is everything.
Frank A Sinicrope1, Mary Jo Turk2
1Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA Sinicrope.Frank@mayo.edu.
Journal for Immunotherapy of Cancer
|August 29, 2024
Summary
Neoadjuvant immunotherapy leverages tumors to build systemic immunity against cancer. Surgical removal of tumors post-treatment may hinder this crucial antitumor response, potentially impacting patient outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Neoadjuvant immunotherapy utilizes the tumor microenvironment to stimulate systemic antitumor immunity.
- Resident memory T cells within tumors are key mediators of response to immune checkpoint inhibitors (ICIs).
- ICIs prime CD8+ T cells and enhance antitumor responses by blocking inhibitory checkpoints.
Purpose of the Study:
- To evaluate the impact of neoadjuvant immunotherapy on intratumoral and systemic antitumor immunity.
- To assess the association between intratumoral T-cell clone expansion and pathological treatment response.
- To investigate the potential consequences of surgical resection on antitumor immunity following neoadjuvant ICI therapy.
Main Methods:
- Analysis of intratumoral immune responses to neoadjuvant immunotherapy.
- Assessment of T-cell priming in tumors and draining lymph nodes.
- Correlation of pathological treatment response with T-cell clone expansion.
- Comparison of neoadjuvant versus adjuvant ICI therapy outcomes in melanoma patients.
Main Results:
- Neoadjuvant ICI treatment enhances both intratumoral and systemic antitumor immunity.
- Expansion of intratumoral T-cell clones correlates strongly with pathological treatment response.
- Neoadjuvant immunotherapy shows high pathological response rates and prolonged survival in advanced melanoma.
- Adjuvant ICI therapy alone may be less effective than neoadjuvant approaches.
Conclusions:
- Neoadjuvant immunotherapy effectively primes the immune system against cancer by utilizing the tumor as an antigen source.
- Surgical resection of the tumor post-neoadjuvant therapy may eliminate critical tumor-specific T cells, potentially compromising long-term antitumor immunity and treatment efficacy.
